Japanese Journal of Cancer Research : Gann. Mar/31/1990; 81(4): 416-424
Combination Treatment with Irritant and Recombinant Interleukin 2 in the Peritoneal Cavity for Evoking Effective Anti‐tumor Activity: Generation of Lymphokine‐activated Killer Cells and Tumor‐specific Killer Cells
Abstract
Abbreviations:
References
- 1. )
Lotze,M. T. ,Grimm,E. A. ,Mazumder,A. ,Strausser,J. L. andRosenberg,S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T‐cell growth factor.Cancer Res.,41,44220–4425(1981).[Google Scholar] - 2. )
Grimm,E. A. ,Mazumer,A. ,Zhang,H. Z. andRosenberg,S. A. Lymphokine activated killer cell phenomenon. Lysis of natural killer‐resistant fresh solid tumor cell by interleukin 2‐activated autologous human peripheral blood lymphocytes.J. Exp. Med.,155,1823–1841(1982).[PubMed][Google Scholar] - 3. )
Cheever,M. A. ,Greenberg,P. D. ,Fefer,A. andGills,S. Augmentation of the anti‐tumor therapeutic efficacy of long‐term cultured T lymphocytes by in vivo administration of purified interleukin 2.J. Exp. Med.,155,968–980(1982).[PubMed][Google Scholar] - 4. )
Ettinghausen,S. E. ,Lipford,E. H. ,Mule,J. J. andRosenberg,S. A. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine‐activated killer (LAK) cells.J. Immunol.,135,3623–3633(1985).[PubMed][Google Scholar] - 5. )
Rosenberg,S. A. ,Mule,J. J. ,Spiess,P. J. ,Reichert,C. M. andSchwarz,S. L. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin 2.J. Exp. Med.,161,1169–1188(1985).[PubMed][Google Scholar] - 6. )
Donohue,J. H. andRosenberg,S. A. The fate of interleukin 2 after in vivo administration.J. Immunol.,130,2203–2208(1983).[PubMed][Google Scholar] - 7. )
Mule,J. J. ,Shu,S. ,Schwarz,S. L. andRosenberg,S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2.Science,225,1487–1489(1984).[PubMed][Google Scholar] - 8. )
Rosenberg,S. A. ,Lotze,M. T. ,Muul,L. M. ,Leitman,S. ,Chang,A. E. ,Ettinghausen,S. E. ,Matory,Y. L. ,Skibber,J. M. ,Shiloni,E. ,Vetto,J. T. ,Seipp,C. A. ,Simpson,C. andReichert,C. M. Observations on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin 2 to patients with metastatic cancer.N. Engl. J. Med.,318,1485–1492(1985).[Google Scholar] - 9. )
Terasaka,R. ,Himeno,K. ,Shiraishi,M. andNomoto,K. Characteristics of xenograft rejection. 1. Augmented cytotoxicity of peritoneal T cells after intraperitoneal injection of booster antigen and/or proteose peptone.Jpn. J. Exp. Med.,51,75–80(1981).[PubMed][Google Scholar] - 10. )
Old,L. J. ,Boyes,E. A. ,Clarke,D. A. andCarswell,E. A. Antigenic properties of chemically induced tumors.Ann. N.Y. Acad. Sci.,101,80–106(1962).[Google Scholar] - 11. )
Gomi,K. ,Morimoto,M. andNomoto,K. Cytotoxic T‐cell‐mediated anti‐tumor effect of levamisole against murine syngeneic fibrosarcoma.Cancer Res.,42,4197–4202(1982).[PubMed][Google Scholar] - 12. )
Naruo,K. ,Hinuma,S. ,Kato,K. ,Koyama,M. ,Tada,H. ,Shiho,O. andTsukamoto,K. Comparison of the biological properties of purified natural and recombinant human interleukin 2.Biochem. Biophys. Res. Commun.,128,257–264(1985).[PubMed][Google Scholar] - 13. )
Kato,K. ,Yamada,T. ,Kawahara,K. ,Onda,K. ,Asano,T. ,Sugino,J. andKakinuma,A. Purification and characterization of recombinant human interleukin 2 produced in Escherichia coli.Biochem. Biophys. Res. Commun.,130,692–699(1985).[PubMed][Google Scholar] - 14. )
Habu,S. ,Fukui,H. ,Shimamura,K. ,Kasai,M. ,Nagai,Y. ,Okamura,K. andTamaoki,N. In vivo effects of anti‐asialo‐GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.J. Immunol.,127,34–38(1981).[PubMed][Google Scholar] - 15. )
Toshitani,A. ,Taniguchi,K. ,Kawano,Y. andNomoto,K. Inverse relationship in H‐2‐associated lysis between NK cells and rIL‐2‐activated killer cells: evidence from in vitro killing and metastatic experiments.Cell. Immunol.,108,188–202(1987).[PubMed][Google Scholar] - 16. )
Brunner,K. T. ,Mauel,J. ,Rudolf,H. andChapuis,B. Studies of allograft immunity in mice. I. Induction, development, and in vitro assay of cellular immunity.Immunology,18,501–515(1970).[PubMed][Google Scholar] - 17. )
Winn,H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.J. Immunol.,86,228–248(1961).[PubMed][Google Scholar] - 18. )
Donohue,J. H. ,Rosenstein,M. ,Chang,A. E. ,Lotze,M. T. ,Robb,R. T. andRosenberg,S. A. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.J. Immunol.,132,2123–2128(1984).[PubMed][Google Scholar] - 19. )
Fujimoto,S. ,Greene,M. I. andSehon,A. H. Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor‐bearing hosts.J. Immunol.,116,791–799(1976).[PubMed][Google Scholar] - 20. )
Hellström,I. ,Sjögren,H. O. ,Warner,G. andHellström,K. E. Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms.Int. J. Cancer,7,226–237(1971).[PubMed][Google Scholar] - 21. )
Sjögren,H. O. ,Hellström,I. ,Bansal,S. C. ,Warner,G. A. andHellström,K. E. Elution of “blocking factors” from human tumor, capable of abrogating tumor cell destruction by specifically immune lymphocytes.Int. J. Cancer,9,274–283(1972).[PubMed][Google Scholar] - 22. )
Yasumoto,K. ,Miyazaki,K. ,Nagashima,A. ,Ishida,T. ,Kuda,T. ,Yano,T. ,Sugimachi,K. andNomoto,K. Induction of lymphokine‐activated killer cells by intra‐pleural instillation of recombinant interleukin‐2 in patients with malignant pleurisy due to lung cancer.Cancer Res.,47,2184–2187(1987).[PubMed][Google Scholar] - 23. )
Uchida,A. andMicksche,M. Intrapleural administration of OK‐432 in cancer patients. Activation of NK cells and reduction of suppressor cells.Int. J. Cancer,31,1–5(1983).[PubMed][Google Scholar]